Leerink Partnrs Weighs in on Repligen FY2024 Earnings

Repligen Co. (NASDAQ:RGEN) – Investment analysts at Leerink Partnrs issued their FY2024 earnings per share (EPS) estimates for Repligen in a research note issued on Tuesday, November 12th. Leerink Partnrs analyst P. Souda anticipates that the biotechnology company will post earnings of $1.55 per share for the year. The consensus estimate for Repligen’s current full-year earnings is $1.44 per share. Leerink Partnrs also issued estimates for Repligen’s Q4 2024 earnings at $0.39 EPS, Q1 2025 earnings at $0.39 EPS, Q2 2025 earnings at $0.47 EPS, Q3 2025 earnings at $0.42 EPS, Q4 2025 earnings at $0.52 EPS, FY2025 earnings at $1.80 EPS and FY2026 earnings at $2.47 EPS.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. The business had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. Repligen’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.23 earnings per share.

A number of other research analysts have also recently issued reports on the stock. Benchmark restated a “hold” rating on shares of Repligen in a report on Monday, August 5th. Wells Fargo & Company initiated coverage on shares of Repligen in a report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target for the company. JPMorgan Chase & Co. raised their price objective on Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 31st. UBS Group decreased their target price on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. Finally, Wolfe Research started coverage on Repligen in a research report on Thursday. They set a “peer perform” rating on the stock. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $190.25.

Repligen Price Performance

Shares of Repligen stock opened at $142.43 on Friday. Repligen has a 12 month low of $113.50 and a 12 month high of $211.13. The business has a fifty day simple moving average of $141.59 and a 200 day simple moving average of $144.78. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Toronto Dominion Bank lifted its position in Repligen by 1.5% during the 2nd quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company’s stock worth $656,000 after buying an additional 75 shares in the last quarter. DekaBank Deutsche Girozentrale raised its stake in shares of Repligen by 1.1% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company’s stock worth $982,000 after purchasing an additional 89 shares in the last quarter. Ballentine Partners LLC boosted its holdings in shares of Repligen by 6.2% in the 3rd quarter. Ballentine Partners LLC now owns 1,807 shares of the biotechnology company’s stock valued at $269,000 after buying an additional 105 shares during the last quarter. Diversified Trust Co grew its stake in shares of Repligen by 3.7% in the second quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company’s stock valued at $372,000 after buying an additional 106 shares in the last quarter. Finally, CWM LLC grew its stake in shares of Repligen by 36.3% in the third quarter. CWM LLC now owns 428 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 114 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Insider Transactions at Repligen

In other news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. This trade represents a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.20% of the stock is owned by insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.